Royalty Pharma Plc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $28.65
- Today's High:
- $29.24
- Open Price:
- $28.97
- 52W Low:
- $28.455
- 52W High:
- $43.6713
- Prev. Close:
- $29.02
- Volume:
- 2108203
Company Statistics
- Market Cap.:
- $12.89 billion
- Book Value:
- 13.948
- Revenue TTM:
- $2.36 billion
- Operating Margin TTM:
- 44.6%
- Gross Profit TTM:
- $1.33 billion
- Profit Margin:
- 10.8%
- Return on Assets TTM:
- 3.78%
- Return on Equity TTM:
- 4.66%
Company Profile
Royalty Pharma Plc had its IPO on 1993-03-25 under the ticker symbol RPRX.
The company operates in the Healthcare sector and Biotechnology industry. Royalty Pharma Plc has a staff strength of 0 employees.
Stock update
Shares of Royalty Pharma Plc opened at $28.97 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $28.65 - $29.24, and closed at $29.15.
This is a +0.45% increase from the previous day's closing price.
A total volume of 2,108,203 shares were traded at the close of the day’s session.
In the last one week, shares of Royalty Pharma Plc have slipped by -3.7%.
Royalty Pharma Plc's Key Ratios
Royalty Pharma Plc has a market cap of $12.89 billion, indicating a price to book ratio of 2.9935 and a price to sales ratio of 8.1383.
In the last 12-months Royalty Pharma Plc’s revenue was $2.36 billion with a gross profit of $1.33 billion and an EBITDA of $1.06 billion. The EBITDA ratio measures Royalty Pharma Plc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Royalty Pharma Plc’s operating margin was 44.6% while its return on assets stood at 3.78% with a return of equity of 4.66%.
In Q2, Royalty Pharma Plc’s quarterly earnings growth was a negative -27.7% while revenue growth was a positive 0.4%.
Royalty Pharma Plc’s PE and PEG Ratio
- Forward PE
- 10.846
- Trailing PE
- 52.2
- PEG
- -0.02
Its diluted EPS in the last 12-months stands at $0.55 per share while it has a forward price to earnings multiple of 10.846 and a PEG multiple of -0.02. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Royalty Pharma Plc’s profitability.
Royalty Pharma Plc stock is trading at a EV to sales ratio of 10.3733 and a EV to EBITDA ratio of 21.3231. Its price to sales ratio in the trailing 12-months stood at 8.1383.
Royalty Pharma Plc stock pays annual dividends of $0.78 per share, indicating a yield of 2.76% and a payout ratio of 16.74%.
Balance sheet and cash flow metrics
- Total Assets
- $17.12 billion
- Total Liabilities
- $1.17 billion
- Operating Cash Flow
- $-63433000.00
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 16.74%
Royalty Pharma Plc ended 2024 with $17.12 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $17.12 billion while shareholder equity stood at $6.28 billion.
Royalty Pharma Plc ended 2024 with $0 in deferred long-term liabilities, $1.17 billion in other current liabilities, 109000.00 in common stock, $2.25 billion in retained earnings and $0 in goodwill. Its cash balance stood at $2.17 billion and cash and short-term investments were $2.91 billion. The company’s total short-term debt was $999,370,000 while long-term debt stood at $6.13 billion.
Royalty Pharma Plc’s total current assets stands at $2.95 billion while long-term investments were $14.00 billion and short-term investments were $735.01 million. Its net receivables were $35.23 million compared to accounts payable of $5.81 million and inventory worth $0.
In 2024, Royalty Pharma Plc's operating cash flow was $-63433000.00 while its capital expenditure stood at $0.
Comparatively, Royalty Pharma Plc paid $0.17 in dividends in 2024.
Other key metrics
- Current Trading Price
- $29.15
- 52-Week High
- $43.6713
- 52-Week Low
- $28.455
- Analyst Target Price
- $51.53
Royalty Pharma Plc stock is currently trading at $29.15 per share. It touched a 52-week high of $43.6713 and a 52-week low of $43.6713. Analysts tracking the stock have a 12-month average target price of $51.53.
Its 50-day moving average was $30.19 and 200-day moving average was $34.54 The short ratio stood at 5.15 indicating a short percent outstanding of 0%.
Around 383% of the company’s stock are held by insiders while 6898.7% are held by institutions.
Frequently Asked Questions About Royalty Pharma Plc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.